Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has authorized Pfizer for the global development, production, and commercialization rights of SSGJ-707 outside of mainland China, receiving a non-refundable upfront payment of $1.25 billion, the largest in China's BD history. The agreement also includes potential milestone payments of up to $4.8 billion and a double-digit percentage sales share based on product sales in authorized regions [7] - The company is expected to achieve a peak sales value of $8.5 billion for SSGJ-707, contributing approximately 35 billion RMB to market value based on a 20x PE after discounting. The domestic peak sales are projected at 5 billion RMB, contributing around 15 billion RMB to market value. The existing business is expected to generate over 2 billion RMB in profit, corresponding to a market value of 30 billion RMB [7] - The company has raised its net profit forecasts for 2025-2026 from 2.63 billion RMB and 2.87 billion RMB to 9.91 billion RMB and 4.47 billion RMB, respectively, with an expected net profit of 5.17 billion RMB in 2027 [7] Financial Projections - Total revenue projections for the company are as follows: - 2023A: 7,836 million RMB - 2024A: 9,108 million RMB (up 16.24% YoY) - 2025E: 19,229 million RMB (up 111.13% YoY) - 2026E: 13,174 million RMB (down 31.49% YoY) - 2027E: 14,885 million RMB (up 12.98% YoY) [1] - Net profit projections are as follows: - 2023A: 1,549 million RMB - 2024A: 2,090 million RMB (up 34.93% YoY) - 2025E: 9,908 million RMB (up 373.98% YoY) - 2026E: 4,474 million RMB (down 54.85% YoY) - 2027E: 5,169 million RMB (up 15.54% YoY) [1] - The latest diluted EPS projections are: - 2023A: 0.65 RMB - 2024A: 0.87 RMB - 2025E: 4.13 RMB - 2026E: 1.87 RMB - 2027E: 2.15 RMB [1]
三生制药（01530）：707重磅BD授权辉瑞，公司发展迈向新征程